ChiCTR2000037565 版本V1.4 版本创建时间2020/10/26 10:09:06 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000037565 

最近更新日期:

Date of Last Refreshed on:

2020-10-26 10:07:05 

注册时间:

Date of Registration:

2020-08-28 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

请与我们联系上传伦理批件。 无创性幽门螺杆菌鉴定与耐药分析的多重基因检测系统的优化与应用

Public title:

Optimization and application of non-invasive Helicobacter pylori identification and drug resistance multiple genetic detection system

注册题目简写:

English Acronym:

研究课题的正式科学名称:

无创性幽门螺杆菌鉴定与耐药分析的多重基因检测系统的优化与应用

Scientific title:

Optimization and application of non-invasive Helicobacter pylori identification and drug resistance multiple genetic detection system

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘宜昕 

研究负责人:

张艳梅 

Applicant:

Liu Yixin 

Study leader:

Zhang Yanmei 

申请注册联系人电话:

Applicant telephone:

+86 19821832081

研究负责人电话:

Study leader's telephone:

+86 15618653286

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

840233635@qq.com

研究负责人电子邮件:

Study leader's E-mail:

15618653286@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市徐汇区东安路130号

研究负责人通讯地址:

上海市静安区延安西路221号复旦大学附属华东医院

Applicant address:

130 Dong'an Road, Xuhui District, Shanghai, China

Study leader's address:

221 Yan'an Road West, Jing'an District, Shanghai, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

复旦大学附属华东医院

Applicant's institution:

Fudan University Huadong Hospital

研究负责人所在单位:

复旦大学枫林校区

Affiliation of the Leader:

Fudan University Fenglin Campus

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2020K127

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

复旦大学附属华东医院伦理审查委员会

Name of the ethic committee:

Ethics Review Committee of Fudan University Huadong Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2020-08-17 00:00:00

伦理委员会联系人:

沙颖豪

Contact Name of the ethic committee:

Sha Yinghao

伦理委员会联系地址:

上海市静安区延安西路168号309室

Contact Address of the ethic committee:

Room 309, 168 Yan'an Road West, Jing'an District, Shanghai, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

复旦大学附属华东医院

Primary sponsor:

Fudan University Huadong Hospital

研究实施负责(组长)单位地址:

上海市静安区延安西路221号复旦大学附属华东医院

Primary sponsor's address:

221 Yan'an Road West, Jing'an District, Shanghai, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

复旦大学附属华东医院

具体地址:

上海市静安区延安西路221号复旦大学附属华东医院

Institution
hospital:

Fudan University Huadong Hospital

Address:

221 Yan'an Road West, Jing'an District

经费或物资来源:

上海申康医院发展中心

Source(s) of funding:

Shanghai Shenkang Hospital Development Center

Target disease:

Dyspepsia associated with Helicobacter pylori infection

Target disease code:

研究类型:

诊断试验

Study type:

Diagnostic test

研究所处阶段:

诊断试验新技术临床试验 

Study phase:

Diagnostic New Technique Clincal Study

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

优化和建立一种无创、全面、快速、低成本的Hp鉴定与耐药性分析的30余重基因检测系统(non-invasive Hp Identification and Drug Resistance Multiple Genetic Detection System,non-invasive Hp-IDMG),规范样本采集、运输、检测、报告等检测流程,并在本市内推广应用,以提升全市Hp的诊疗水平和能力。  

Objectives of Study:

Optimize and establish a non-invasive, comprehensive, rapid and low-cost Hp identification and drug resistance analysis of more than 30 multiple genes detection system (non-invasive Hp Identification and Drug Resistance Multiple Genetic Detection System, non-invasive Hp-IDMG). Standardize the testing procedures of sample collection, transportation, testing and reporting, and popularize and apply them in this city to improve the level and ability of Hp diagnosis and treatment.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)2020年10月~2022年9月来华东医院消化科门诊并进行胃镜检查、胃黏膜活检和13C-呼气试验的消化不良症状的患者
(2)年龄不限,男女不限。
(3)消化不良诊断的采用2007年中华医学会消化分会胃肠动力组的定义:临床表现为上腹部疼痛或烧灼感、餐后上腹饱胀和早饱感的症候群,可伴食欲不振、嗳气、恶心或呕吐等症状。

Inclusion criteria

1. Patients in Huadong Hospitals Gastroenterology Clinic from October 2020 to September 2022 who had dyspeptic symptoms and undergone gastroscopy, gastric mucosal biopsy and 13C-breath test;
2. Any age;
3. The diagnosis of dyspepsia is based on the definition of the gastrointestinal motility group of the Digestive Branch of the Chinese Medical Association in 2007: clinical manifestations are symptoms of pain or burning in the upper abdomen, fullness of the upper abdomen after a meal, and early satiety, which may be accompanied by loss of appetite, belching, and nausea Or vomiting and other symptoms.

排除标准:

(1)内镜证实有活动性出血者;
(2)已接受过Hp根除治疗者;
(3)最近1个月曾经服用铋剂、质子泵抑制剂、H2受体拮抗剂以及抗生素者;
(4)曾对本次治疗所用的药物有过敏史或皮试阳性患者;
(5)孕期及哺乳期患者。

Exclusion criteria:

1. Patients with active bleeding confirmed by endoscopy;
2. Patients who have received Hp eradication therapy;
3. Patients who have taken bismuth, proton pump inhibitors, H2 receptor antagonists and antibiotics in the past month;
4. Patients with a history of allergies or a positive skin test during this treatment;
5. Patients during pregnancy and lactation.

研究实施时间:

Study execute time:

From 2020-10-01 00:00:00 To 2022-09-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-10-01 00:00:00 To 2021-09-30 00:00:00  

诊断试验:

Diagnostic Tests:

金标准或参考标准(即可准确诊断某疾病的单项方法或多项联合方法,在本研究中用于诊断是否有该病的临床参考标准):

(1)幽门螺杆菌鉴定参考标准(多项联合): 1. 幽门螺杆菌体外培养+显微镜检查,观察到典型幽门螺杆菌形态。 2. C13-呼气试验:按照《C13-尿素呼气试验的操作规程》的流程和步骤进行检测。 3. 组织病理染色镜检:由病理科专业的资深技师染色镜检和诊断。 (2)幽门螺杆菌耐药性检查参考标准: E-test法体外药敏试验,读取M-H培养基上抑菌圈与E-test纸条相交处的数值即为待检Hp对该药物的最低抑菌浓度(MIC)。根据美国临床和实验室标准协会(CLSI)2013年版及相关文献的判断标准,判断耐药的MIC值为:克拉霉素MIC ≥ 1 μg/mL、甲硝锉MIC ≥ 8 μg/mL、喹诺酮类MIC ≥ 1 μg/L,阿莫西林MIC ≥ 8 μg/mL。

Gold Standard or Reference Standard (The clinical reference standards required to establish the presence or absence of the target condition in the tested population in present study):

(1)Reference standard for the identification of Helicobacter pylori (multiple combinations): 1. Helicobacter pylori in vitro culture combined with microscopic examination. 2. C13- Breath Test. (2)Reference standard of Helicobacter pylori drug resistance examination: In vitro drug susceptibility test (E-test).

指标试验(即本研究的待评估诊断试验,无论为方法、生物标志物或设备,均请列出名称):

幽门螺杆菌鉴定与耐药性分析的多重基因检测系统

Index test:

non-invasive Hp Identification and Drug Resistance Multiple Genetic Detection System(non-invasive Hp-IDMG)

目标人群(可以是某种疾病患者或正常人群,详细描述其疾病特征,注意应纳入符合分布特点的全序列病例,具有良好的代表性)

2020年10月~2022年9月来华东医院消化科门诊就诊的消化不良患者,年龄不限,男女不限。临床表现为上腹部疼痛或烧灼感、餐后上腹饱胀和早饱感的症候群,可伴食欲不振、嗳气、恶心或呕吐等症状。

例数:

Sample size:

1000

Target condition (The target condition is a particular disease or disease stage that the index test will be intended to identify. Please specify the characteristics in detail; the population should has a complete spectrum and good representative):

Patients with dyspepsia who come to the outpatient department of Gastroenterology Department of Huadong Hospital from October 2020 to September 2022. No age and gender limit. The clinical manifestations are symptoms of upper abdominal pain or burning sensation, upper abdominal fullness after a meal and early satiet

容易混淆的疾病人群(即与目标疾病不易区分的一种或多种不同疾病,应避免采用正常人群对照的病例-对照设计):

浅表性胃炎和胃溃疡患者

例数:

Sample size:

1000

Population with condition difficult to distinguish from the target condition, the normal population in a case-control study design should be avoid:

Patients with superficial gastritis and gastric ulcer

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China 

Province:

Shanghai 

City:

 

单位(医院):

复旦大学附属华东医院 

单位级别:

三级甲等 

Institution
hospital:

Fudan University Huadong Hospital

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

幽门螺杆菌阳性率

指标类型:

主要指标

Outcome:

Helicobacter pylori positive rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

幽门螺杆菌耐药率

指标类型:

主要指标

Outcome:

Helicobacter pylori drug resistance rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

胃黏膜活检样本

组织:

胃黏膜

Sample Name:

Gastric mucosal biopsy sample

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

牙菌斑样本和唾液样本

组织:

口腔

Sample Name:

Dental plaque and saliva sample

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

粪便样本

组织:

Sample Name:

Stool sample

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由华东医院消化科胃镜室医生对同期进入胃镜室进行检查的患者留取连续样本(即同期进入研究的连续样本)

Randomization Procedure (please state who generates the random number sequence and by what method):

The doctor in the Gastroscopy Room of the Gastroenterology Department of Huadong Hospital will collect continuous samples of patients who enter the gastroscopy room for examination at the same time (ie, continuous samples that enter the study at the same time)

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

ResMan临床试验公共管理平台(www.medresman.org)/试验完成后6个月内

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Clinical Trial Management Public Platform/Six months after the study is completed

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采取电子病例报告表(eCRF)进行构建;保证在线质量控制和在线实时质量控制,采用基于互联网的电子采集和管理系统(Electronic Data Capture, EDC)

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data is constructed using electronic case report form (eCRF),and online quality control and online real-time quality control are guaranteed through internet-based electronic data capture and management system (Electronic Data Capture, EDC).

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2020-08-28 23:45:47